Amgen Announces Significant Survival Benefit for Lung Cancer Drug IMDELLTRA in Phase 3 Trial

Amgen Inc. (NASDAQ:AMGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 2, Amgen announced new interim results from the global Phase 3 DeLLphi-304 trial for its drug IMDELLTRA (tarlatamab-dlle). The data were presented at the 2025 ASCO Annual Meeting and published in The New England Journal of Medicine.

It showed that IMDELLTRA reduced the risk of death by 40% and extended median overall survival by over 5 months compared to standard-of-care/SOC chemotherapy in patients with small cell lung cancer/SCLC who had progressed on or after one line of platinum-based chemotherapy. IMDELLTRA is a first-in-class targeted immunotherapy engineered by Amgen.

It binds to DLL3, which is a protein expressed on the surface of SCLC cells in ~85-96% of patients but minimally on healthy cells, and CD3 on T-cells. This dual binding activates T-cells to specifically target and kill DLL3-expressing SCLC cells. The DeLLphi-304 trial is a global Phase 3, randomized, controlled, and open-label clinical study. It enrolled 509 patients. The results support the potential conversion of IMDELLTRA’s accelerated FDA approval, which was granted last year based on tumor response rates, into a full approval.

Amgen Inc. (NASDAQ:AMGN) discovers, develops, and manufactures human therapeutics globally.

While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.